Source: International Congress 2018 – Latest developments in cystic fibrosis
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
C. Biglia (Orbassano (TO), Italy), C. Bena (Orbassano (TO), Italy), G. Bonizzoni (Orbassano (TO), Italy), M. Bellocchia (Orbassano (TO), Italy), A. Grande (Orbassano (TO), Italy), F. Traversa (Orbassano (TO), Italy), E. Clivati (Orbassano (TO), Italy), G. Bandelli (Orbassano (TO), Italy), S. Demichelis (Orbassano (TO), Italy), C. Albera (Orbassano (TO), Italy), B. Messore (Orbassano (TO), Italy). Safety and efficacy of intravenous (IV) Fosfomycin in adult cystic fibrosis patients. 3408

Member's Comments

No comment yet.

Related content which might interest you: The prevalence and characteristics of intravenous (IV) antibiotics allergy in adult patient with cystic fibrosis (CF) Source: Annual Congress 2012 - Cystic fibrosis (adults and children): risk factors and clinical problems Year: 2012 Home intravenous antibiotic treatments in cystic fibrosis adult patients Source: Eur Respir J 2002; 20: Suppl. 38, 158s Year: 2002 Safety, tolerability and efficacy of intravenous aminophylline in adult patients with pulmonary exacerbations of cystic fibrosis Source: International Congress 2014 – Cystic fibrosis: basic science, physiology and clinical aspects Year: 2014 Long-term efficacy and safety of tobramycin 300mg/4mL nebuliser solution in patients with cystic fibrosis and chronic Pseudomonas aeruginosa infection Source: Annual Congress 2012 - Cystic fibrosis (adults and children): new aspects of risk factors, treatments and diagnosis Year: 2012 Pharmacokinetics and antibacterial activity of inhaled liposomal ciprofloxacin hydrochloride in healthy volunteers and in cystic fibrosis (CF) patients Source: Annual Congress 2009 - Cystic fibrosis: disease progression and novel therapies Year: 2009 Interim data from a long-term safety, tolerability, and efficacy study of liposomal amikacin for inhalation in cystic fibrosis patients with chronic pseudomonas aeruginosa infection Source: International Congress 2014 – Cystic fibrosis: assessment and treatment Year: 2014 Once-daily tobramycin in the treatment of adult patients with cystic fibrosis Source: Eur Respir J 2002; 19: 303-309 Year: 2002 Long-term administration of aerosolised tobramycin in patients with cystic fibrosis Source: Eur Respir J 2005; 26: Suppl. 49, 619s Year: 2005 Pharmacokinetics of oral voriconazole in adults with cystic fibrosis Source: Annual Congress 2010 - Cystic fibrosis: lung disease infection and more Year: 2010 Safety and tolerability of pirfenidone (PFD) in patients with idiopathic pulmonary fibrosis (IPF) receiving commonly used concomitant medications Source: Annual Congress 2012 - Diffuse parenchymal lung disease: clinical profiles and collagen vascular disease Year: 2012 Improvement in pulmonary function after IV antibiotic treatment in cystic fibrosis patients Source: Eur Respir J 2002; 20: Suppl. 38, 342s Year: 2002 Efficacy and safety of oral sildenafil in cystic fibrosis childrenwith mild to moderate lung disease Source: Virtual Congress 2020 – Clinical monitoring and new therapies for cystic fibrosis Year: 2020 The pharmacokinetic of the main oral antibiotics in children with cystic fibrosis. Source: International Congress 2019 – Treatments, adherence and psychosocial aspects of cystic fibrosis Year: 2019 A UK experience of temocillin in the treatment of adult cystic fibrosis patients Source: Annual Congress 2008 - Cystic fibrosis: new mechanisms, monitoring and treatment tools Year: 2008 Comparative efficacy of different methods of ceftazidime administration in children with cystic fibrosis Source: Eur Respir J 2001; 18: Suppl. 33, 126s Year: 2001 Efficacy and safety of inhaled ENaC inhibitor BI 1265162 in patients with cystic fibrosis: BALANCE-CF 1, a randomised, phase II study Source: Eur Respir J, 59 (2) 2100746; 10.1183/13993003.00746-2021 Year: 2022 A randomised comparison of two tobramycin formulations in cystic fibrosis (CF) patients with chronic pseudomonas aeruginosa (PA) infection for pharmacokinetic and therapeutic equivalence Source: Annual Congress 2013 –Cystic fibrosis: basic and applied science Year: 2013 Oral L-arginine therapy in patients with cystic fibrosis: a pilot study Source: Eur Respir J 2002; 20: Suppl. 38, 340s Year: 2002 Ataluren in nonsense mutation cystic fibrosis patients not receiving chronic inhaled tobramycin: Evaluation of exacerbations and lung function Source: International Congress 2016 – Cystic fibrosis: inflammation, microbiology, management and monitoring Year: 2016 Safety and tolerability of nintedanib in patients with idiopathic pulmonary fibrosis in the USA Source: Eur Respir J, 52 (1) 1702106; 10.1183/13993003.02106-2017 Year: 2018